Browse by author
Lookup NU author(s): Emeritus Professor Alan Craft
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant fibrous histiocytoma (MFH-B). This prospective study evaluates the effect of doxorubicin and cisplatin on these tumours. Thirty-seven patients, age less than or equal to65 years, with spindle cell sarcoma of bone, except osteosarcoma, or MFH-B, were included. Chemotherapy consisted of doxorubicin and cisplatin every 3 weeks for six cycles. Resection was performed after three cycles. In 15 patients with metastases, response assessment showed three complete responses (CR), four stable disease (SD), five progression; three were not evaluable. Median time to progression was 30 months (95% Confidence Interval (CI), 851 months) for the operable non-metastatic patients; median survival 41 months (95% CI, 16-82 months). Median time to progression in the metastatic group was 10 months (95% CI, 0-18 months) and median survival was 14 months (95% CI, 4-45 months). This study suggests a limited role for doxorubicin and cisplatin in metastatic high-grade spindle cell sarcoma of bone, other than osteosarcoma or MFH-B cases. (C) 2004 Elsevier Ltd. All rights reserved.
Author(s): Nooij, M. A., Whelan, J., Bramwell, V. H. C., Taminiau, A. T., Cannon, S., Hogendoorn, P. C. W., Pringle, J., Uscinska, B. M., Weeden, S., Kirkpatrick, A., von Glabbeke, M., Craft, A. W.
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
Year: 2005
Volume: 41
Issue: 2
Pages: 225-230
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
URL: http://dx.doi.org/10.1016/j.ejca.2004.08.026
DOI: 10.1016/j.ejca.2004.08.026
PubMed id: 15661546
Altmetrics provided by Altmetric
